Business Wire

NV-ROBOSENSE

8.1.2020 15:02:09 CET | Business Wire | Press release

Share
RoboSense Announces World ’s First Public Road Test of Vehicle Equipped With Smart Lidar Sensor at CES 2020

RoboSense (http://www.robosense.ai ), the leading autonomous driving LiDAR perception solution provider, announced today the world’s first public road test of a vehicle equipped with a Smart LiDAR Sensor at CES 2020 . The RoboSense Smart LiDAR car, featuring the award-winning RS-LiDAR-M1 Smart LiDAR , will be running outside the Las Vegas Convention Center daily during CES 2020, showing the latest technological progress in autonomous vehicle LiDAR. Simultaneous exhibitions will be held at RoboSense’s CES Booth #6138 at the LVCC, North Hall showcasing the real-time 3D point cloud data on a vehicle equipped with the multi solid state LiDAR fusion system.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200108005303/en/

First MEMS Smart LiDAR Sensor to Incorporate Sensor Hardware, AI Perception Algorithms, & IC Chipsets

The RoboSense RS-LiDAR-M1 Smart LiDAR is the world’s first MEMS Smart LiDAR Sensor to incorporate sensor hardware, AI perception algorithms, and IC chipsets, transforming conventional LiDAR sensors from an information collector to a complete data analysis and comprehension system, providing essential information for autonomous vehicle decision-making faster than ever before. The RS-LiDAR-M1 is the winner of the CES Innovation Award for two consecutive years in a row, 2019 and 2020.

RoboSense Co-Partner and Vice President of R&D, Dr. Leilei Shinohara, said, “After optimization based on large amounts of data, RoboSense’s algorithm performance and software stability and reliability have proven to have many key advantages. Developed by RoboSense after more than a decade of exhaustive research in perception technology, it has combined the advantages of deep-learning-based AI algorithm with the traditional algorithms to keep functional safety. Since 2017, RoboSense’s algorithms have gained more than 100 global partners for various types of autonomous driving scenario certifications.”

At CES and on the streets of Las Vegas, the RoboSense RS-LiDAR-M1 Smart is demonstrating that it is the world’s first and only Smart LiDAR capable of real road tests on open roads .

128 Laser Beam System & Fastest Mass-produced Short-range LiDAR for Blind Spot Detection

During CES 2020, RoboSense128-beams LiDAR RS-Ruby and the short-range Blind Spot LiDAR RS-BPearl also go on public road demo, meanwhile there is also a simultaneous exhibition at RoboSense Booth. This super high-performance 128-beam LiDAR RS-Ruby possesses an ultra-high resolution of 0.1° and the range performance of 200m for a 10% reflectivity target.

The RS-BPearl, the first mass-produced short-range LiDAR for blind-spot detection, reaches the minimum detection range of less than several centimeters, with hemispheric FOV coverage of 90° * 360°, which not only precisely identifies objects around the vehicle’s body, but can also detect the actual height information in particular scenarios, such as with bridge tunnels and culverts.

RoboSense Partner Demonstrations at CES 2020

RoboSense has partnerships with numerous industry leaders who will be announcing partnerships or co-demonstrating with RoboSense at CES, including ON Semiconductor, Xilinx, Horizon, AutoX, and Freetech.

Wade Appelman, Vice President of ISG, SensL Division, ON Semiconductor, said, “The combo of RoboSense LiDAR with the ON Semiconductor RD Series SiPM family of products will perform much better than the older APD technology employed by legacy LiDAR manufacturers using mechanical scanning architectures, further enhancing the performance of the RS-LiDAR-M1 to be one of the best in the automotive LiDAR market.”

About RoboSense

The world’s leading autonomous driving LiDAR perception solution provider. http://www.robosense.ai .

Social Media:

https://www.facebook.com/RoboSenseLiDAR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye